Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma

Duodenal adenocarcinoma (ADC) represents only 0.3% of gastrointestinal neoplasms. With the frequency being higher between the ages of 40 and 60, it is predominantly located in the second part of the duodenum and around the periampullary region. Symptoms are nonspecific, so the majority of patients p...

Full description

Saved in:
Bibliographic Details
Published in:Ecancermedicalscience 2018-03, Vol.12, p.816
Main Authors: Velandia, Carlos, Morales, Rafael Delgado, Coello, Carlos, Mendoza, Armando Gil, Pérez, Gabriel, Aguero, Emperatriz
Format: Article
Language:English
Subjects:
Abdomen
Antigens
Breast cancer
Cancer therapies
Case Report
Chemotherapy
Endoscopy
Lymphatic system
Metastasis
Mortality
Oncology
Pancreas
Pathology
Patients
Studies
Surgery
Tumors
Ultrasonic imaging
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Duodenal adenocarcinoma (ADC) represents only 0.3% of gastrointestinal neoplasms. With the frequency being higher between the ages of 40 and 60, it is predominantly located in the second part of the duodenum and around the periampullary region. Symptoms are nonspecific, so the majority of patients present with advanced disease. Neoadjuvant chemotherapy is a therapeutic option that has not been well studied. The global literature includes only isolated reports on this subject. This is why we are presenting the following case: a 60-year-old female patient with a locally advanced, inoperable duodenal ADC received neoadjuvant chemotherapy. Having presented a favourable response as observed in the post-neoadjuvant extension studies, a pancreaticoduodenectomy was performed without any perioperative complications and with satisfactory progress. The final biopsy reported a complete pathological response. After being monitored for 34 months, the patient was free from locoregional and distant metastatic disease. During the last weeks of monitoring, she developed a second primary breast tumour, which has been corroborated by immunohistochemistry.
ISSN:1754-6605
1754-6605
DOI:10.3332/ecancer.2018.816